Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, New York, New York.
Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York.
J Am Coll Cardiol. 2015 Jul 14;66(2):184-92. doi: 10.1016/j.jacc.2015.05.030.
In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk.
除了积极的生活方式和非脂类风险因素的改变，他汀类药物治疗可改善急性冠脉综合征后的心血管疾病结局。尽管治疗具有明确的益处，但当代注册研究显示，他汀类药物治疗在二级预防中的使用率和依从性都很低。在他汀类药物治疗的随机对照试验中，包括中等强度他汀类药物加依折麦布治疗，高达 40%的受试者存在不依从的情况。为了最大限度地降低心血管疾病风险，必须制定持久的策略来解决二级预防中降低血脂的差距问题。
Ann Pharmacother. 2012-10-2
J Manag Care Pharm. 2008-10
Turk Kardiyol Dern Ars. 2009-3
J Gen Intern Med. 2025-7-25
Zotero 插件